|
Post by peppy on May 18, 2018 20:06:23 GMT -5
I hope Kendall uses this and other studies to talk more about afrezza, first phase and second phase insulin response. RAA only second phase.
|
|
|
Post by mnholdem on May 18, 2018 22:00:23 GMT -5
I'm certain that he won't forget to mention the shorter duration. After all, everyone luvs a little tail (chuckle).
|
|
|
Post by kc on Jun 8, 2018 23:05:23 GMT -5
|
|
|
Post by centralcoastinvestor on Jun 8, 2018 23:51:45 GMT -5
Eli Lilly and Company? Maybe they are sad about losing Dr. Kendall.
|
|
|
Post by agedhippie on Jun 9, 2018 8:52:04 GMT -5
Eli Lilly and Company? Maybe they are sad about losing Dr. Kendall. They are there as the Boehringer Ingelheim Pharmaceuticals, Inc./Eli Lilly stand. Top tip; never partner with a company whose name is long enough to get your name truncated off the end. Eli Lilly partner with Boehringer Ingelheim in the non-insulin diabetes drug space.
|
|
|
Post by kc on Jun 9, 2018 12:10:05 GMT -5
What makes you think they are in that particular booth? (Boehringer Ingelheim Pharmaceuticals, Inc./Eli Lilly stand. ) They are independent companies and normally exhibit separately. They do have the relationship on the biosimilar insulin. to my knowledge they have not exhibited together before? They also offer to many insulin products not to have an exhibit since they are One of the big three companies. www.lillydiabetes.com/lilly-diabetes-medicines.aspx
|
|
|
Post by letitride on Jun 9, 2018 15:48:24 GMT -5
What makes you think they are in that particular booth? (Boehringer Ingelheim Pharmaceuticals, Inc./Eli Lilly stand. ) They are independent companies and normally exhibit separately. They do have the relationship on the biosimilar insulin. to my knowledge they have not exhibited together before? They also offer to many insulin products not to have an exhibit since they are One of the big three companies. www.lillydiabetes.com/lilly-diabetes-medicines.aspxMaybe they didnt see a future in the diabetes market with Dr. Kendall gone and Afrezza taking over, so they decided to just stand down.
|
|
|
Post by agedhippie on Jun 9, 2018 19:52:20 GMT -5
What makes you think they are in that particular booth? (Boehringer Ingelheim Pharmaceuticals, Inc./Eli Lilly stand. ) They are independent companies and normally exhibit separately. They do have the relationship on the biosimilar insulin. to my knowledge they have not exhibited together before? They also offer to many insulin products not to have an exhibit since they are One of the big three companies. www.lillydiabetes.com/lilly-diabetes-medicines.aspxThere is a longstanding partnership between Boehringer and Lilly Diabetes.
|
|
|
Post by kc on Jun 9, 2018 22:39:06 GMT -5
What makes you think they are in that particular booth? (Boehringer Ingelheim Pharmaceuticals, Inc./Eli Lilly stand. ) They are independent companies and normally exhibit separately. They do have the relationship on the biosimilar insulin. to my knowledge they have not exhibited together before? They also offer to many insulin products not to have an exhibit since they are One of the big three companies. www.lillydiabetes.com/lilly-diabetes-medicines.aspxThere is a longstanding partnership between Boehringer and Lilly Diabetes. I believe the partnership is only on one product and that is the Lantus Biosimular product basaglar. I’m not sure the relationship but I believe it’s at Eli Lilly handles the US distribution. Eli Lily is much bigger than just the one product so they would be marketing all of their own products and the joint partnership on one product. www.basaglar.com/en/
|
|
|
Post by agedhippie on Jun 10, 2018 9:52:10 GMT -5
There is a longstanding partnership between Boehringer and Lilly Diabetes. I believe the partnership is only on one product and that is the Lantus Biosimular product basaglar. I’m not sure the relationship but I believe it’s at Eli Lilly handles the US distribution. Eli Lily is much bigger than just the one product so they would be marketing all of their own products and the joint partnership on one product. www.basaglar.com/en/Jardiance, at least, is a collaboration as well. Both of them contributed various molecules to the partnership. This is from the latest press release announcing a joint action sponsoring the University of Oxford to investigate the effects of Jardiance in adults with chronic kidney disease. Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in diabetes that centers on compounds representing several of the largest diabetes treatment classes. This alliance leverages the strengths of two of the world's leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Find out more about the alliance at www.boehringer-ingelheim.com or www.lilly.com
|
|